VHAM
Van Hulzen Asset Management’s Pacira BioSciences PCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-150
| Closed | -$2.83K | – | 863 |
|
|
2024
Q4 | $2.83K | Sell |
150
-71,022
| -100% | -$1.34M | ﹤0.01% | 890 |
|
|
2024
Q3 | $1.07M | Buy |
71,172
+7,006
| +11% | +$105K | 0.08% | 155 |
|
|
2024
Q2 | $1.84M | Buy |
64,166
+29,784
| +87% | +$852K | 0.12% | 120 |
|
|
2024
Q1 | $1.01M | Buy |
34,382
+447
| +1% | +$13.1K | 0.07% | 167 |
|
|
2023
Q4 | $1.15M | Buy |
33,935
+2,294
| +7% | +$77.4K | 0.08% | 144 |
|
|
2023
Q3 | $971K | Buy |
31,641
+10,664
| +51% | +$327K | 0.07% | 150 |
|
|
2023
Q2 | $841K | Buy |
20,977
+2,283
| +12% | +$91.5K | 0.07% | 134 |
|
|
2023
Q1 | $763K | Buy |
18,694
+4,313
| +30% | +$176K | 0.07% | 138 |
|
|
2022
Q4 | $555K | Buy |
14,381
+852
| +6% | +$32.9K | 0.06% | 161 |
|
|
2022
Q3 | $720K | Buy |
13,529
+702
| +5% | +$37.4K | 0.09% | 140 |
|
|
2022
Q2 | $748K | Buy |
12,827
+85
| +0.7% | +$4.96K | 0.09% | 134 |
|
|
2022
Q1 | $972K | Buy |
12,742
+178
| +1% | +$13.6K | 0.1% | 113 |
|
|
2021
Q4 | $756K | Buy |
12,564
+5,798
| +86% | +$349K | 0.08% | 137 |
|
|
2021
Q3 | $379K | Buy |
+6,766
| New | +$379K | 0.06% | 189 |
|